• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida implant meets primary endpoint in late-stage trial

June 14, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months.

In the 153-patient trial, 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group.

“The data from this trial confirms previous clinical research demonstrating our 3-year Durasert insert for posterior segment uveitis may significantly help patients suffering from this devastating disease — the third leading cause of blindness,” president & CEO Nancy Lurker said in prepared remarks. “Our market research indicates strong interest in using the product driven by the results of our 1st Phase III clinical trial. We continue to expect the submission of the European Market Authorization Application by the end of June, and we remain on track to also file a New Drug Application with the FDA in the calendar 4th quarter of 2017.”

The Watertown, Mass.-based company also reported that intraocular pressure elevation was 2.4 mm Hg at 6 months for the Durasert group and 1.3 mm Hg for the sham group. Also, 41.6% of patients in the Durasert required IOP-lowering therapy at any time during the 1st 6 months follow-up and 34.6% for the sham group.

In patients with a natural lens at baseline, 4.9% in the group treated with Durasert needed a cataract surgery through 6 months versus 8.6% in the sham group.

“The results of the 2nd Phase III study confirm the efficacy and safety profile of the Durasert 3-year insert demonstrated in the 1st Phase III study. Consistent, durable control of chronic posterior segment uveitis is a critical goal of treatment. The 3-year Durasert insert has the potential to be the 1st product approved to help prevent the recurrence of this devastating condition for up to three years with a single intravitreal injection,” primary investigator Dr. Jyotirmay Biswas said.

“Chronic posterior uveitis is challenging to treat as the disease tends to wax and wane over time.  Durasert 3-year insert is a single-injection office-based treatment that can last 2-3 years. Therefore, it addresses the need to help prevent recurrences over an extended time period, rather than to treat them episodically, and may represent an exciting new approach to manage these patients,” Dr.  Glenn J. Jaffe, from the Duke University School of Medicine, said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: pSivida Corp.

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS